Market closed
Lucid Diagnostics/$LUCD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Ticker
$LUCD
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
70
Website
LUCD Metrics
BasicAdvanced
$43M
Market cap
-
P/E ratio
-$1.13
EPS
1.42
Beta
-
Dividend rate
Price and volume
Market cap
$43M
Beta
1.42
52-week high
$1.58
52-week low
$0.63
Average daily volume
587K
Financial strength
Current ratio
1.181
Quick ratio
1.104
Long term debt to equity
31.729
Total debt to equity
206.153
Interest coverage (TTM)
-1,504.33%
Management effectiveness
Return on assets (TTM)
-101.02%
Return on equity (TTM)
-1,007.83%
Valuation
Price to revenue (TTM)
8.591
Price to book
-0.81
Price to tangible book (TTM)
-0.79
Price to free cash flow (TTM)
-0.803
Growth
Revenue change (TTM)
179.27%
Earnings per share change (TTM)
-19.69%
3-year revenue growth (CAGR)
175.65%
3-year earnings per share growth (CAGR)
-6.62%
What the Analysts think about LUCD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Lucid Diagnostics stock.
LUCD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LUCD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LUCD News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Lucid Diagnostics stock?
Lucid Diagnostics (LUCD) has a market cap of $43M as of December 14, 2024.
What is the P/E ratio for Lucid Diagnostics stock?
The price to earnings (P/E) ratio for Lucid Diagnostics (LUCD) stock is 0 as of December 14, 2024.
Does Lucid Diagnostics stock pay dividends?
No, Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Lucid Diagnostics dividend payment date?
Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders.
What is the beta indicator for Lucid Diagnostics?
Lucid Diagnostics (LUCD) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.